Monoclonal antibodies for immunosuppression. by Waldmann, H, Hale, G, Clark, M, Cobbold, S, Benjamin, R, Friend, P, Bindon, C, Dyer, M, Qin, S, Bruggemann, M

THE USE OF MONOCLONAL ANTILYMPHOCYTE ANTIBODIES IN CLINICAL IMMUNOSUPPRESSION by Friend, P, Calne, R, White, D, Hale, G, Waldmann, H

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation. by Hale, G, Waldmann, H, Friend, P, Calne, R

Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. by Novitzky, N, Thomas, V, Stubbings, H, Hale, G, Waldmann, H

Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. by Novitzky, N, Thomas, V, Stubbings, H, Hale, G, Waldmann, H

T-cell depletion of stem cell grafts with campath-1H "in the bag" followed by cyclosporin immunosuppression remains a cost effective strategy in transplantation by Novitzky, N, Thomas, V, Hale, G, Waldmann, H

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. by Newman, D, Isaacs, J, Watson, P, Meyer, P, Hale, G, Waldmann, H

“…Nine consecutive corneal grafts were rapidly destroyed despite systemic immunosuppression with corticosteroid, cyclophosphamide, azathioprine and cyclosporin A. …”

CAMPATH-1 monoclonal antibodies in bone marrow transplantation. by Hale, G, Waldmann, H

“…Graft rejection could be partly overcome by additional immunosuppression either with CsA or total lymphoid irradiation (TLI). …”

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. by Watson, C, Bradley, J, Friend, P, Firth, J, Taylor, C, Bradley, JR, Smith, K, Thiru, S, Jamieson, N, Hale, G, Waldmann, H, Calne, R

“…They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. …”

Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. by Murphy, C, Greiner, K, Plskova, J, Duncan, L, Frost, A, Isaacs, J, Rebello, P, Waldmann, H, Hale, G, Forrester, J, Dick, A

“…A reduction in concomitant immunosuppression was possible for 11 patients (65%) following TNFr-Ig therapy. …”

CAMPATH: from concept to clinic. by Waldmann, H, Hale, G

“…Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. …”

Isolation of low-frequency class-switch variants from rat hybrid myelomas. by Hale, G, Cobbold, S, Waldmann, H, Easter, G, Matejtschuk, P, Coombs, R

“…An IgG2b variant antibody having the same specificity as CAMPATH-1 for human lymphocytes and monocytes is active in antibody-dependent cell-mediated killing (unlike the parental IgG2a) and may prove to be a valuable therapeutic antibody for immunosuppression and treatment of leukaemia and lymphoma.…”

Campath-1H therapy in refractory ocular inflammatory disease. by Dick, A, Meyer, P, James, T, Forrester, J, Hale, G, Waldmann, H, Isaacs, J

“…Long lasting remissions were achieved in eight patients, in whom baseline immunosuppression could subsequently be reduced to minimal levels. …”

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. by Keymeulen, B, Candon, S, Fafi-Kremer, S, Ziegler, A, Leruez-Ville, M, Mathieu, C, Vandemeulebroucke, E, Walter, M, Crenier, L, Thervet, E, Legendre, C, Pierard, D, Hale, G, Waldmann, H, Bach, J, Seigneurin, J, Pipeleers, D, Chatenoud, L

“…The anti-CD3 antibody administration induced short-lasting immunosuppression and minor yet clear-cut signs of T-cell activation that preceded viral reactivation. …”

Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. by Hale, G, Bright, S, Chumbley, G, Hoang, T, Metcalf, D, Munro, A, Waldmann, H

“…As well as being used for in vitro treatment of bone marrow to remove T cells, CAMPATH 1 could potentially be applied to other experimental and clinical situations where depletion of lymphoid cells is required, including serotherapy to achieve immunosuppression for organ transplants or to treat lymphocytic leukemias.…”

Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. by Lockwood, C, Thiru, S, Stewart, S, Hale, G, Isaacs, J, Wraight, P, Elliott, J, Waldmann, H

“…Conventional immunosuppression for systemic vasculitides is limited by substantial side-effects, cumulative drug toxicity and refractoriness in some patients. …”

The effect of treatment with Campath-1H in patients with autoimmune cytopenias. by Willis, F, Marsh, J, Bevan, D, Killick, S, Lucas, G, Griffiths, R, Ouwehand, W, Hale, G, Waldmann, H, Gordon-Smith, E

“…We describe 21 patients with severe and life-threatening autoimmune cytopenias resistant to standard immunosuppression who were treated with the monoclonal antibody Campath-1H. …”

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial. by Friend, P, Hale, G, Waldmann, H, Gore, S, Thiru, S, Joysey, V, Evans, D, Calne, R

“…However, patients who received this additional immunosuppression experienced a significantly higher incidence of serious infections than controls, this negating any benefit from the treatment in terms of graft survival. …”

In vitro and in vivo depletion of T cells. by Arnold, R, Bunjes, D, Wiesneth, M, Hertenstein, B, Theobald, M, Heimpel, H, Hale, G, Waldmann, H

“…To prevent gvhd and associated infections without increased graft rejection, a protocol of combined in vivo/ex vivo T-cell depletion (Campath IgG 20 mg i.v. for 5 days and Campath IgM T-cell depleted graft) with no further immunosuppression was initiated. Up to now 22 adult patients (median age 39 years, range 21 to 51) have been transplanted. …”

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related to... by Cull, G, Haynes, A, Byrne, J, Carter, G, Miflin, G, Rebello, P, Hale, G, Waldmann, H, Russell, N

“…As BEAM may be insufficiently immunosuppressive to permit durable engraftment in the allogeneic setting, patients received additional pretransplant immunosuppression with the anti-CD52 antibody CAMPATH-1G from day -5 to day -1. …”